The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.Here's the latest list of major oversold players in this sector, having an RSI near or below 30.Inspire Medical Systems Inc (NYSE:INSP)Profound Medical Corp (NASDAQ:PROF)         Biomarin Pharmaceutical Inc (NASDAQ:BMRN)Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and see how they compare.Photo via Shutterstock ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the Cheap Stocks to Buy for High Returns in 2026. On March 12, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released positive data from ongoing trials of VOXZOGO, which is the company’s approved treatment for achondroplasia. ​Achondroplasia is a genetic condition that causes dwarfism and stunted growth in children. The recent data reported by the company suggests that starting treatment before the age of 2 years maximizes benefits, including height gains, ...

Core Viewpoint - BioMarin Pharmaceutical has decided to discontinue mid-stage trials of its bone disorder treatment Voxzogo due to reports of patients experiencing hip joint issues, leading to a 4% drop in its share price [1]. Group 1: Treatment and Trials - BioMarin was testing Voxzogo in patients with Turner Syndrome, SHOX-deficiency, and ACAN-deficiency, which are genetic conditions associated with severe short stature and abnormal bone development [2]. - During the trials, several patients experienced slipped capital femoral epiphysis, a condition where the hip joint's ball slips off the thigh bone [3]. - Despite halting trials for certain conditions, BioMarin will continue testing Voxzogo in patients with Noonan syndrome and unexplained short stature [3]. Group 2: Regulatory Background - The U.S. FDA approved Voxzogo in 2021 for patients with achondroplasia, a type of dwarfism [4]. - Recently, the FDA also approved Ascendis Pharma's Yuviwel, marking it as the second treatment for achondroplasia to receive U.S. approval [4].

Core Insights - BioMarin Pharmaceutical is focusing on disciplined expense management and efficient cost allocations to achieve leveraged growth, expecting earnings per share growth at roughly three times revenue growth in 2025 [1] - The company anticipates "high single digits" growth for both Skeletal Conditions and Enzyme Therapies, with the planned Amicus acquisition expected to add two high-growth products [2][7] - BioMarin reported a total revenue growth of 13% in 2025, with Skeletal Conditions growing by 26% and Enzyme Therapies by 9% [3] Financial Performance - BioMarin's revenue growth in 2025 was driven by a strong performance in its Skeletal Conditions unit, which includes the product VOXZOGO [3] - The company expects continued operating margin expansion and cash flow growth alongside revenue growth [1] Strategic Initiatives - The company is executing a three-pillar strategy focused on growth, innovation, and value commitment, which includes recent revenue momentum and multiple clinical milestones [4] - The planned acquisition of Amicus is seen as a strategic move to enhance product offerings in rare genetic conditions, with expectations of slight dilution in 2026 but substantial accretion thereafter [7][14] Product Pipeline and Development - BioMarin is advancing its pipeline with key programs such as BMN 351 for Duchenne muscular dystrophy and BMN 401 for ENPP1 deficiency, with significant data expected in the near term [5][16] - The company is also developing a long-acting version of VOXZOGO, BMN 333, aimed at being superior to existing therapies [10] Market Dynamics - VOXZOGO revenue is expected to be weighted towards the second half of the year, with approximately 75% of its revenue coming from outside the U.S. [17] - The company is focusing on expanding its geographic reach and improving diagnosis rates for conditions like Fabry disease through the Amicus acquisition [13]

Question-and-Answer SessionTo kick it off with an overview question before we kind of go into some of the specifics. Just can you give us a brief overview of the key highlights of BioMarin's progress over 2025 and what we can look forward to in 2026?Brian MuellerCFO & Executive VP Yes. Thanks, Ellie. Appreciate it. Thanks for having us. Thanks to those of you joining in person. Really pleased to be talking to you today at this point in the year as we transition out of what was a very successful 2025 for the ...

BioMarin Pharmaceutical FY Conference Summary Company Overview - **Company**: BioMarin Pharmaceutical (NasdaqGS: BMRN) - **Date of Conference**: March 11, 2026 - **Key Speakers**: Brian (CFO), Cristin (Chief Commercial Officer) Key Highlights of 2025 - **Revenue Growth**: Total revenue grew by 13% in 2025, with Voxzogo revenue increasing by 26% and enzyme therapies by 9% [2][3] - **Profitability Improvement**: Earnings per share growth outpaced revenue growth, achieving over 2 times leverage on the bottom line after adjusting for special items [3] - **Amicus Acquisition**: Announcement of the acquisition of Amicus, expected to close in Q2 2026, which will add two high-growth rare disease assets to BioMarin's portfolio [3][4] 2026 Outlook - **Revenue Guidance**: Expected revenue growth in both enzyme therapies and skeletal conditions at 7%-8%, with a total revenue headwind of about 3% due to decreasing royalty and other revenues [4] - **Voxzogo Revenue Guidance**: Projected revenue for Voxzogo in 2026 is between $975 million and $1.025 billion, influenced by international market access negotiations and competitive impacts [14][15] - **Pipeline Advancements**: Anticipated phase 3 readouts for hypochondroplasia and BMN 401, with potential for significant market impact [5][47] Competitive Landscape - **Voxzogo Competition**: Voxzogo faces competition, but only 25% of its revenues are from the U.S., which is subject to competition, representing about 7% of total revenue [8][15] - **Market Positioning**: BioMarin is confident in Voxzogo's established position in the achondroplasia community, emphasizing the complexity of switching treatments for patients [7][8] Clinical Pipeline - **Hypochondroplasia**: Estimated total addressable patient population of 14,000, with a focus on increasing disease awareness and shortening diagnosis times [24][25] - **BMN 351**: A second-generation exon skipping therapy for Duchenne muscular dystrophy, showing promising early data with a target of 10% dystrophin expression [6] - **ENPP1 Deficiency**: Anticipated phase 3 data readout for BMN 401, with an estimated addressable patient population of 2,000-2,500 globally [47][48] Amicus Acquisition Impact - **Revenue Contribution**: Amicus products generated over $600 million in 2025, expected to enhance BioMarin's revenue portfolio significantly [18] - **Operational Synergies**: Anticipated operational expense synergies from integrating Amicus, with a focus on leveraging existing global capabilities [30][32] Financial Strategy - **Deleveraging Plan**: Target to reduce debt to less than 2.5 times within two years post-acquisition, with a focus on maintaining operational profitability [56][57] - **Future Business Development**: Continued interest in pipeline clinical stage transactions to enhance long-term revenue growth [58] Additional Insights - **Palynziq Expansion**: Recent label expansion for Palynziq to include adolescents, with an estimated 1,500 eligible patients in the U.S. [39][41] - **Seasonality in Revenue**: Historical trends indicate a ramp-up in revenue towards Q4, with a typical step down in Q1 due to international order timing [49][50] This summary encapsulates the key points discussed during the BioMarin Pharmaceutical FY Conference, highlighting the company's growth trajectory, competitive positioning, and strategic initiatives for the upcoming year.

Core Insights - BioMarin is optimistic about its growth trajectory in 2026, building on a strong performance in 2025 with total revenue growth of 13% [1] - The skeletal conditions business unit, which includes Voxzogo, experienced significant growth of 26% in 2025, while enzyme therapies grew by 9% [1] Corporate Strategy - The company's corporate strategy is framed around three pillars: growth, innovation, and value commitment [2] - BioMarin anticipates strong growth from both its skeletal conditions and enzyme therapies business units, with guidance indicating high single-digit growth for both [2] - The expected closing of the Amicus acquisition in Q2 is anticipated to enhance the portfolio with two high-growth products [2]

BioMarin Pharmaceutical Conference Call Summary Company Overview - **Company**: BioMarin Pharmaceutical (NasdaqGS: BMRN) - **Date**: March 09, 2026 - **Key Speakers**: Brian Mueller (CFO), Cristin Hubbard (CCO) Key Points Industry and Company Performance - BioMarin reported a **13% revenue growth** in 2025, with the Skeletal Conditions unit (including VOXZOGO) growing by **26%** and Enzyme Therapies by **9%** [4][5] - The company anticipates **high single-digit growth** for both Skeletal Conditions and Enzyme Therapies in 2026 [4] Strategic Growth Pillars - BioMarin's corporate strategy is built on three pillars: **growth, innovation, and value commitment** [4] - The company is preparing for the **Amicus acquisition** in Q2 2026, which is expected to enhance its portfolio with two high-growth products in rare genetic conditions [5] Product Pipeline and Innovations - Recent approval of **PALYNZIQ** for adolescents and upcoming **Phase 3 data readouts** for VOXZOGO in hypochondroplasia and BMN 401 for ENPP1 deficiency [5][6] - Ongoing development of **BMN 351** for Duchenne muscular dystrophy and **BMN 333**, a long-acting CNP for achondroplasia [6] Market Dynamics and Patient Retention - BioMarin is focused on patient retention for VOXZOGO, emphasizing that **efficacy and safety** are key factors influencing caregivers' decisions to switch therapies [10][11] - Approximately **two-thirds** of KOLs and caregivers believe that switching therapies is unlikely if patients are doing well on current treatments [11] Achondroplasia Market Insights - The company is working to build a broader health narrative around achondroplasia beyond just growth, focusing on overall health benefits [12][14] - BioMarin has a long history with VOXZOGO, having started its development program over **15 years ago**, and is now filing for full approval based on long-term data [20] Hypochondroplasia Opportunity - The Phase 3 trial for hypochondroplasia is expected to yield data in the **first half of 2026**, with strong enrollment indicating market excitement [25][26] - The company is focusing on **disease awareness** and improving the diagnosis journey for hypochondroplasia patients [28][30] Amicus Acquisition and Market Expansion - The acquisition of Amicus is expected to enhance BioMarin's market presence, with **Galafold** currently available in **40 countries** and BioMarin operating in **80** [38] - The integration of Amicus products is anticipated to unlock additional value through deeper market penetration and improved diagnosis efforts [39][43] Financial Projections - The Amicus acquisition may be slightly dilutive in **2026** but is expected to be accretive in the first 12 months and substantially accretive thereafter [45] - BioMarin expects **VOXZOGO revenues** in the second half of 2026 to exceed the first half, primarily due to international order timing [64][66] Manufacturing and Operational Strategy - BioMarin is recognized for its high-quality manufacturing capabilities and plans to leverage these skills for Amicus products, particularly POMP [51][53] Clinical Data and Future Expectations - Upcoming data cuts for **BMN 351** and pivotal Phase 3 data for **ENPP1 deficiency** are anticipated, with a focus on patient diagnosis and treatment initiation [54][57] Conclusion BioMarin Pharmaceutical is positioned for continued growth through strategic acquisitions, a robust product pipeline, and a commitment to enhancing patient care in rare genetic conditions. The company is focused on leveraging its manufacturing expertise and expanding its market presence while maintaining a strong emphasis on patient retention and treatment efficacy.

Core Viewpoint - BioMarin Pharmaceutical is focusing on business development to strengthen its pipeline and expects to continue pursuing earlier-stage deals while managing debt post-Amicus acquisition [1][7]. Business Development and Growth Strategy - The company has established "multiple pillars of growth," including enzyme therapies and a skeletal conditions business led by Voxzogo, with BMN 333 in development [2][3]. - CEO Alexander Hardy emphasized a strategic refresh that has made business development a key growth driver, evidenced by the Inozyme and pending Amicus acquisitions [3][4]. Competitive Landscape - Voxzogo is facing new FDA-approved competition, but BioMarin anticipates a gradual switching process due to strong adherence and safety data, along with a five-year market lead [5][17]. - The company has prepared for competitive dynamics and believes that the long-term durability and safety of Voxzogo will be crucial in retaining patients [17]. Financial Outlook - BioMarin's 2026 framework anticipates a 3% revenue headwind from the removal of ROCTAVIAN expectations and Kuvan erosion, yet expects core enzyme and skeletal franchises to grow at mid-to-high single digits [6][8]. - The company targets a 40% operating margin in 2026, excluding the impact of Amicus, attributing margin expansion to a refined financial strategy and cost transformation program [14][15]. Pipeline Developments - Key upcoming clinical catalysts include a Phase 3 readout for hypochondroplasia, the weekly-dosed BMN 333 program, and a pediatric Phase 3 readout for BMN 401 in the first half of the year [5][23]. - BioMarin aims for BMN 333 to deliver superior efficacy with a weekly dosing regimen, and the study is powered for a 2.25 cm annualized growth velocity, which is approximately 50% better than Voxzogo [23]. Market Penetration and Expansion - Only about 25% of Voxzogo revenue is generated in the U.S., indicating significant potential for international expansion and deeper market penetration [13]. - The company is focused on increasing its presence in existing markets and launching into new countries to maximize revenue opportunities [13].

Core Insights - The FDA has granted multiple approvals for new treatments across various therapeutic areas, including oncology and rare genetic disorders, in late February and early March 2026 Group 1: Boehringer Ingelheim Pharmaceuticals Inc. - The FDA granted accelerated approval to Hernexeos as a first-line treatment for adult patients with advanced non-small cell lung cancer (NSCLC) with HER2 mutations on February 26, 2026 [2] - Hernexeos is the first targeted therapy for HER2-mutant advanced NSCLC in the first-line setting, with HER2 mutations occurring in approximately 2-4% of NSCLC cases [3] Group 2: Ascendis Pharma A/S - Ascendis received accelerated approval for Yuviwel, a once-weekly treatment for children aged 2 years and older with achondroplasia on February 27, 2026 [4] - Yuviwel is the first and only approved therapy providing continuous systemic exposure to C-type natriuretic peptide (CNP) over a weekly dosing interval [6] Group 3: BioMarin Pharmaceutical Inc. - BioMarin expanded the indication of Palynziq to include pediatric patients aged 12 years and older with phenylketonuria (PKU) on February 27, 2026 [7] - Palynziq is the only enzyme substitution therapy approved to reduce blood phenylalanine concentrations in PKU patients, generating $433 million in revenue in 2025, up from $355 million in 2024 [9] Group 4: Novo Nordisk A/S - Novo Nordisk received FDA approval for three new indications for Sogroya, a long-acting growth hormone, on February 27, 2026 [10] - Sogroya is now approved for children aged 2.5 years and older with Idiopathic Short Stature, short stature born Small for Gestational Age, and growth failure associated with Noonan Syndrome [11] - The once-weekly administration of Sogroya aims to improve adherence compared to daily growth hormone injections [12] Group 5: Johnson & Johnson - The FDA approved Tecvayli plus Darzalex Faspro for adults with relapsed or refractory multiple myeloma on March 5, 2026 [13] - Tecvayli received accelerated approval in October 2022 as a subcutaneous treatment for patients with RRMM who have undergone multiple prior therapies [14] - Darzalex Faspro is already approved for multiple indications in multiple myeloma, enhancing treatment options for patients [15]